Existing tumor-based ICI outcome predictors, such as tumor mutational burden (TMB)5,6 or tumor programmed death ligand 1 (PD-L1) status7, alone or in combination, do not sufficiently explain the heterogeneity of the observed outcomes, let alone enable more personalized therapy selection. The gene discussed is CD274; the disease is neoplasm.